Allovir Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALVR Nasdaq 8731 https://www.allovir.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allovir Inc

AlloVir's Posoleucel Shows Early Safety In Kidney Transplant Recipients - Jun 7th, 2022 4:07 pm
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients - Jun 7th, 2022 12:30 pm
AlloVir Reports First Quarter 2022 Financial Results - May 5th, 2022 11:00 am
AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel - Apr 21st, 2022 3:35 pm
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients - Apr 20th, 2022 11:00 am
Here's Why We're Watching AlloVir's (NASDAQ:ALVR) Cash Burn Situation - Apr 4th, 2022 11:40 pm
AlloVir Appoints Shawn Tomasello to Its Board of Directors - Mar 31st, 2022 11:00 am
AlloVir (ALVR) Begins Study to Prevent Six Viral Infections - Mar 23rd, 2022 1:56 pm
AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients - Mar 22nd, 2022 11:00 am
AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference - Feb 11th, 2022 12:00 pm
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook - Feb 10th, 2022 12:00 pm
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation - Jan 5th, 2022 12:30 pm
AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference - Jan 3rd, 2022 9:05 pm
AlloVir Announces Departure of Chief Medical Officer Augustin Melian - Dec 16th, 2021 9:05 pm
AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting - Dec 11th, 2021 6:00 pm
Allovir Insider Sold Over $465K In Company Stock - Nov 17th, 2021 4:57 pm
AlloVir to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference - Nov 15th, 2021 12:00 pm
Allovir Insider Trades $300K In Company Stock - Nov 10th, 2021 4:48 pm
AlloVir Reports Third Quarter 2021 Financial Results - Nov 5th, 2021 11:00 am
Morgan Stanley: These 2 ‘Strong Buy’ Stocks Could Double From Here - Oct 29th, 2021 1:47 pm